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Background. Acute retroviral syndrome (ARS) is associated with human immunodeficiency virus type 1 (HIV-1) subtype and 
disease progression, but the underlying immunopathological pathways are poorly understood. We aimed to elucidate associations 
between innate immune responses during hyperacute HIV-1 infection (hAHI) and ARS.
Methods. Plasma samples obtained from volunteers (≥18.0 years) before and during hAHI, defined as HIV-1 antibody negative 
and RNA or p24 antigen positive, from Kenya, Rwanda, Uganda, Zambia, and Sweden were analyzed. Forty soluble innate immune 
markers were measured using multiplexed assays. Immune responses were differentiated into volunteers with stronger and compar-
atively weaker responses using principal component analysis. Presence or absence of ARS was defined based on 11 symptoms using 
latent class analysis. Logistic regression was used to determine associations between immune responses and ARS.
Results. Of 55 volunteers, 31 (56%) had ARS. Volunteers with stronger immune responses (n = 36 [65%]) had increased odds of 
ARS which was independent of HIV-1 subtype, age, and risk group (adjusted odds ratio, 7.1 [95% confidence interval {CI}: 1.7–28.8], 
P = .003). Interferon gamma-induced protein (IP)-10 was 14-fold higher during hAHI, elevated in 7 of the 11 symptoms and inde-
pendently associated with ARS. IP-10 threshold >466.0 pg/mL differentiated stronger immune responses with a sensitivity of 84.2% 
(95% CI: 60.4–96.6) and specificity of 100.0% (95% CI]: 90.3–100.0).
Conclusions. A stronger innate immune response during hAHI was associated with ARS. Plasma IP-10 may be a candidate bio-
marker of stronger innate immunity. Our findings provide further insights on innate immune responses in regulating ARS and may 
inform the design of vaccine candidates harnessing innate immunity.
Keywords.  HIV-1; acute infection; immune responses; acute retroviral syndrome; IP-10.
Virologic and immunologic events during acute human im-
munodeficiency virus type 1 (HIV-1) infection (AHI) are as-
sociated with disease pathogenesis. During the first 10  days 
of HIV-1 infection (eclipse phase), the virus replicates at the 
infection site and in local lymphoid tissues before undergoing 
systemic dissemination. Subsequent stages of AHI can be de-
fined by detection of virus RNA only (Fiebig stage I), virus RNA 
and p24 antigen (Fiebig stage II), and development of HIV-1 
specific antibodies (Fiebig stages III-V) [1]. In 40–90% of cases, 
acute retroviral syndrome (ARS) presents before or during peak 
plasma viremia 2–3 weeks after HIV-1 infection [2–5]. The 
number and severity of symptoms have been correlated with 
rapid disease progression [6–8]. AHI symptoms are also more 
common in HIV-1 subtype A1 compared to subtype C and D 
infections [4].
AHI is further characterized by an induction of innate im-
mune responses, including activation of dendritic cells, macro-
phages, and natural killer (NK) cells [9–11]. The earliest 
systemic innate immune perturbations occur during the eclipse 
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cytokines, and chemokines are induced with elevations in mul-
tiple analytes creating a cytokine storm [12–14]. This systemic 
activation has been shown to have antiviral activity, enhance 
other innate immune responses, and shape adaptive immunity 
to control virus replication [15–19]. However, the exaggerated 
response also has immunopathological consequences by pro-
moting provirus transcription, enhancing HIV-1 replication 
and driving CD4+ T-cell depletion [20–22]. Little is known 
about involvement of innate immune responses in the regu-
lation of AHI symptoms. We hypothesized that activation of 
strong innate immune responses are associated with AHI symp-
toms. We sought to test this hypothesis in a hyperacute HIV-1 
infection (hAHI) study involving volunteers enrolled into co-
horts from 4 African and 1 European countries.
METHODS
Study Design and Ethical Considerations
Data and samples were obtained from African and Swedish 
adult (≥18  years old) volunteers enrolled in acute and early 
HIV-1 infection studies. African volunteers were enrolled 
2006–2011 at sites in Kenya, Rwanda, Uganda, and Zambia 
under IAVI’s protocol C [23]. Volunteers diagnosed with AHI 
before 2011 and identified from patient medical records at 
Skåne University Hospital in Lund/Malmö, Sweden, were in-
cluded. Volunteers with hAHI diagnosis were eligible (defined 
as HIV-1 antibody negative and RNA [Fiebig stage I] or p24 an-
tigen [Fiebig stage II] positive). Available matched preinfection 
samples from volunteers were also included in the analysis. All 
protocol C volunteers provided written informed consent for 
the use of their samples for biomedical research. Protocol C 
sites received approvals from respective country-specific ethics 
review boards [23]. Ethical approval for the Swedish cohort 
was obtained from the Lund University Ethical Review Board, 
Sweden (Diarienummer [Dnr] 2013/772).
Characteristics of Volunteers
Protocol C data were obtained from a centralized and curated 
repository. De-identified data from the Swedish volunteers 
were obtained from an electronic patient register (InfCareHIV) 
and medical records. Baseline variables included date of birth, 
sex, ethnicity, HIV-1 RNA, HIV-1 p24 antigen, and antibody 
test results, date of HIV-1 diagnosis, transmission risk group 
(serodiscordant, men who have sex with men [MSM], and het-
erosexual relationships), and AHI symptoms.
HIV-1 Subtyping
HIV-1 env sequences (V1-V3, approximately 940 base pairs) 
were generated, and HIV-1 subtype were phylogenetically de-
termined as previously described [24]. In brief, HIV-1 RNA 
was extracted, reverse transcribed, polymerase chain reac-
tion (PCR) amplified and sequenced using established proto-
cols. Generated sequences were aligned with HIV-1 subtype 
reference sequences from the Los Alamos HIV-1 sequence da-
tabase (https://www.hiv.lanl.gov/content/index). The general 
time reversible (GTR) model of nucleotide substitution with 
gamma distributed rate heterogeneity was used to infer max-
imum likelihood trees. Branch support was assessed using the 
approximate likelihood ratio test based on the Shimodaira-
Hasegawa (aLRT-SH) method, with branch support of ≥ .90 
considered significant [25].
Acute Retroviral Syndrome
For protocol C volunteers, AHI symptoms were ascertained 
2–6 weeks following the estimated date of infection using a 
standardized questionnaire [4]. For Swedish volunteers, med-
ical records were reviewed using the protocol C questionnaire 
as a template; documented AHI symptoms were extracted sep-
arately by 2 investigators. AHI symptoms reported at the inci-
dent visit or in follow-up visits (but within 6 weeks of incident 
visit) were extracted. Case files without a reported symptom 
were considered negative for that symptom. Inconsistencies 
were discussed and a consensus documented.
Acute retroviral syndrome (ARS) was defined based on 11 
AHI symptoms. Previous studies have used various defin-
itions for ARS including volunteers reporting any symptom, 
≥2 symptoms, ≥3 symptoms, or a combination of fever with 
other symptom(s) [2, 26, 27]. A potential limitation of discrete 
classification methods is the inability to account for unobserved 
linkages between symptoms. Latent class analysis (LCA), a 
structural equation modelling approach, was therefore applied 
to group volunteers based on the number of AHI symptoms and 
other unobserved linkages, defined as those with or without 
ARS.
Innate Immune Responses
Cryopreserved plasma samples collected from whole 
blood treated with ethylenediaminetetraacetic acid 
(EDTA) were used. Multiplexed analysis was done in du-
plicates and measured by electrochemiluminescence using 
the MesoScaleDiscovery (MSD) multispot 40-plex assay 
(MesoScaleDiagnostics, LLC) according to manufacturer’s 
instructions [28]. All samples were processed from the IAVI 
Human Immunology Laboratory, London, United Kingdom. 
Analyte concentration read-outs, along with respective 
lower (LLOQ) and upper (ULOQ) limits of quantification, 
were inferred from standard curves. Analyte concentrations 
below the LLOQ were assigned half the LLOQ concentra-
tion, whereas those above the ULOQ were assigned the 
ULOQ value. The mean of the duplicate observations were 
analyzed.
Data Analysis
First, ARS was defined based on the number of AHI symp-
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disentangled into those with and without ARS. Second, associ-
ations between log10 analyte concentrations with AHI symptoms 
and with ARS were assessed using Wilcoxon rank sum tests. 
Analytes suggestive of an association with any of the 11 AHI 
symptoms and with ARS were further explored using principal 
component analysis (PCA). The PCA differentiated volunteers 
into those with stronger and comparatively weaker immune re-
sponses. Third, logistic regression was applied to determine asso-
ciations between immune response and ARS. HIV-1 subtype, risk 
group, ethnicity, geographic region, and HIV-1 RNA were dichot-
omized to maximize precision. A threshold of P < .10 was used to 
select variables from univariable to multivariable models. Finally, 
individual analytes were assessed for prognostic performance in 
differentiating stronger immune responses using receiver oper-
ating characteristic area under the curve (ROC-AUC).
All analyses were done in Stata/IC version 15.1 (StataCorp 
LP, California), and outputs generated using GraphPad Prism 
version 8.4.2 (GraphPad Software, California). A  2-sided 
type 1 error of 5% was considered statistically significant. 
Due to sample size limitations and consistent with previous 
publications, no formal corrections for multiple comparisons 
were done [14, 26].
RESULTS
Characteristics of Study Volunteers
Fifty-five volunteers were eligible. The majority of volunteers 
were diagnosed with HIV-1 by p24 (Fiebig II, n = 42 [76%]) and 
had a matched preinfection sample (n = 31 [56%]), collected 
at median 47 (interquartile range [IQR], 22–120) days before 
HIV-1 infection. A complete set of baseline variables were avail-
able for all volunteers, except for HIV-1 RNA that was missing 
from 62% of volunteers (Table 1). No significant differences in 
baseline characteristics of volunteers with missing versus with 
HIV-1 RNA data were found (Supplementary Table 1), and 
HIV-1 RNA was therefore excluded from further analysis. Most 
volunteer HIV-1 genetic sequences clustered with subtype A1 
(n = 33 [60%], Figure 1). The majority of HIV-1 subtype A1 
sequences (n = 26) were from Kenya, whereas all HIV-1 sub-
type B sequences (n = 8) were from Sweden.
Table 1. Characteristics of Volunteers Diagnosed With Hyperacute HIV-1 Infection From Africa (Rwanda, Uganda, Zambia, and Kenya) and Sweden by 
Fiebig Staging (N = 55)
Baseline Variables Fiebig I (N = 13) Fiebig II (N = 42) Overall (N = 55)
Age (y) Median (IQR) 22.6 (20.9–27.1) 29.3 (25.1–34.1) 28.1 (23.0–34.1)
Age group (y) 18.0–24.9 7 (54) 10 (24) 17 (31)
25.0–34.9 4 (31) 22 (52) 26 (47)
35.0–44.9 1 (8) 5 (12) 6 (11)
45.0+ 1 (8) 5 (12) 6 (11)
Gender Female 0 (0) 4 (10) 4 (7)
Male 13 (100) 38 (90) 51 (93)
Year of infection <2009 4 (31) 15 (36) 19 (35)
2009–2010 7 (54) 18 (43) 25 (45)
2011+ 2 (15) 9 (21) 11 (20)
Ethnicity African 13 (100) 29 (69) 42 (76)
Arab/Asian 0 (0) 1 (2) 1 (2)
Caucasian 0 (0) 12 (29) 12 (22)
Risk groupa DC 2 (15) 12 (29) 14 (25)
HET 1 (8) 3 (7) 4 (7)
MSM 10 (77) 24 (57) 34 (62)
UNK 0 (0) 3 (7) 3 (5)
Country Sweden 0 (0) 13 (31) 13 (24)
Africanb 13 (100) 29 (69) 42 (76)
HIV-1 RNA (log10 cpm) Median (IQR) 4.0 (3.8–4.6) 6.1 (5.9–7.0) 5.0 (4.0–6.0)
HIV-1 RNA group (log10 cpm) ≤5.0 11 (85) 0 (0) 11 (20)
>5.0 2 (15) 8 (19) 10 (18)
Missing 0 (0) 34 (79) 34 (62)
Matched preinfection samplec No 2 (15) 22 (52) 24 (44)
Yes 11 (85) 20 (48) 31 (56)
Matched preinfection periodd Median (IQR) 85 (22–158) 41 (22–81) 47 (22–120)
Abbreviations: cpm, copies per milliliter; HIV-1, human immunodeficiency virus type 1; IQR, interquartile range.
aRisk group data (DC [serodiscordant couples], HET [heterosexual], MSM (men who have sex with men] and UNK [unknown]). 
bAfrican countries (protocol C sites from Rwanda [n = 4], Uganda [n = 5], Zambia [n = 4] and Kenya [n = 29]). 
cMatched preinfection samples from Kenya (n = 29), Rwanda (n = 1) and Zambia (n = 1). 
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Acute Retroviral Syndrome
Overall, 43 (78%) volunteers had at least one AHI symptom. 
The median number of symptoms was 4 (IQR, 1–7). The 
most common symptom was fever (n = 37 [67%]; Figure 
2A). Using LCA, volunteers were grouped into those with 
ARS (n = 31 [56%]; median symptoms per volunteer, 6 
[IQR, 5–8]) and without ARS (n = 24 [44%]; 0.5 [IQR, 
0–2.5], Figure 2B). Nine of the 11 AHI symptoms were 
significantly higher in volunteers with ARS. Myalgia dem-
onstrated the strongest, whereas skin rash and pharyn-
gitis demonstrated no discriminatory potential for ARS. 
Notably, fever was common in both groups (with and 
without ARS), suggesting a weak discriminatory ability for 
ARS (Figure 2C).
Figure 2. (a) Distribution of volunteers diagnosed with hyperacute HIV-1 infection by AHI symptoms; (b) a schematic illustration of the distribution of AHI symptoms for all 
volunteers (black curve) and by grouping of volunteers resulting from latent class analysis (LCA, for those without acute retroviral syndrome, [ARS, blue] and for those with 
ARS [red]). The numbers denote median (interquartile ranges) symptoms per volunteer for all volunteers (in black), for those without ARS (in blue) and for those with ARS 
(in red); and (c) Graph comparing the distribution of AHI symptoms between volunteers that were defined to be with and without ARS (Fisher exact test P < .05 [*], P < .01 
[**], and P < .001 [***], N = 55). ARS was defined based on the 11 AHI symptoms and other unobserved linkages between symptoms using LCA. Incremental latent group 
models were assessed to predict the goodness of fit. The model with 2 latent groups was the best fit as it had the lowest BIC value (660.5) compared to 3 (678.6), 4 (699.2), 
or 5 (714.7) groups. Volunteers were grouped based on their predicted posterior probabilities into those with ARS (n = 31 [56%]) and those without ARS (n = 24 [44%]). 
Abbreviations: AHI, acute human immunodeficiency virus type 1; ARS, acute retroviral syndrome; CI, confidence interval; HIV-1, human immunodeficiency virus type 1; LCA, 
latent class analysis.
Figure 1. (A) Phylogenetic tree showing relatedness of HIV-1 partial envelope sequences (V1-V3 region) from individuals with hyperacute HIV-1 infection from Africa and 
Sweden (N = 55), with HIV-1 subtype reference sequences from the Los Alamos database (N = 158); and (B) summary table showing the distribution of HIV-1 partial env 
(V1-V3 region) subtypes of individuals with hyperacute infection from Africa and Sweden (N = 55). Branches are colored according to HIV-1 env subtype as follows: gray (refer-
ences), red (subtype A1), dark blue (subtype B), orange (subtype C), green (subtype D), light blue (recombinant BG), purple (recombinant A2D), and brown (recombinant AE). Tip 
labels are colored according to the country of origin as follows: gray (references; only those clustering with volunteer sequences shown), green (Rwanda), orange (Uganda), 
blue (Kenya), purple (Zambia), and red (Sweden). *Unable to amplify HIV-1 env region from two volunteers, though previous gag/pol/nef sequence data suggests subtype C 
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Innate Immune Responses During Hyperacute HIV-1 Infection
SAA, CRP, VCAM-1, and ICAM-1 concentrations were higher 
than the ULOQ in >90% of volunteers and therefore excluded 
from further analysis. Compared to matched preinfection re-
sponses, 16 analytes were significantly elevated during hAHI 
(Figure 3A; Supplementary Table 2). A 14-fold higher median 
level of Interferon gamma-induced protein (IP)-10  was ob-
served during hAHI compared to HIV-1 preinfection (2400 
[IQR, 251–2400] vs 168 [IQR, 86–204] pg/mL). Substantial 
between-individual variation in analyte responses was observed 
(Figure 3B). Macrophage inflammatory protein (MIP)-1β, 
Eotaxin-3, MIP-1α, interleukin (IL)-8, IL-1β, IL-2, IL-4, IL-6, 
IL-8, IL-12p70, IL-13, and tumor necrosis factor (TNF)-α were 
positively correlated with each other (Supplementary Figure 1).
Associations Between Innate Immune Responses and Acute Retroviral 
Syndrome
Overall, 18 analytes were higher in volunteers with any AHI symp-
toms compared to those without symptoms (Supplementary Figure 
2). IP-10 activation stood out, with plasma concentrations being 
significantly higher across 7 of the 11 AHI symptoms (Figure 4A). 
Further, there were significantly higher IP-10 (P < .001), interferon 
(IFN)-γ (P = .020), granulocyte-macrophage colony-stimulating 
factor (GM-CSF) (P = .033), IL-12 (P = .043), IL-15 (P = .037), 
Eotaxin-3 (P = .002), Flt-1 (P = .025), IL-10 (P = .047), IL12p70 
(P = .027) and IL-13 (P = .047) plasma concentrations amongst 
volunteers with versus without ARS (Figure 4B; Supplementary 
Table 3). After adjusting for HIV-1 subtype, age, and risk group, ele-
vated IP-10 was independently associated with ARS (adjusted coeffi-
cient, 4.7 [95% confidence interval {CI}: 0.8–8.6], P = .002, Table 2).
Significantly elevated analytes in volunteers with any of the 
11 symptoms and in those with ARS were  analyzed by PCA. 
Two principal components (PCs) were determined: PC1 (IP-10, 
IFN-γ, IL-12, IL-15, and Flt-1); and PC2 (Eotaxin-3, IL-13, and 
IL-12p70, Supplementary Figure 3). Both PCs were significantly 
associated with ARS, suggesting a synergistic effect of multiple 
analytes on ARS (more so for Eotaxin-3, IL-13 and IL-12p70, 
which were not significantly associated with ARS when assessed 
independently, Supplementary Table 4).
Furthermore, volunteers were grouped into those with 
higher PC1 loading and those with higher PC2 loading. 
Volunteers with higher PC1 loading had significantly higher 
median plasma concentration for the majority of the 40 
analytes compared to those with higher PC2 loading (Figure 
5A, Supplementary Table 5). Hence, PC1 analytes differentiated 
volunteers into those with stronger immune responses (n = 36 
[65%]) and comparatively weaker immune responses (n = 19 
[35%], Figure 5B). After controlling for HIV-1 subtype, age and 
risk group, volunteers with stronger innate immune responses 
had increased odds of ARS (adjusted odds ratio, 7.1 [95% CI: 
1.7–28.8], P = .003, Table 3).
A B
Figure 3. (A) Plot illustrating fold-differences in median plasma biomarker concentration from matched pre-infection and hyperacute HIV-1 infection samples. Red bars demon-
strate fold difference in analytes that had higher plasma concentrations during hyperacute HIV-1 infection compared to the pre-infection samples. Blue bars denote fold-difference 
in analytes that had higher concentrations in the pre-infection samples compared to hyperacute HIV-1 infection samples. (B) Graphs illustrating analytes that were significantly 
higher during hyperacute HIV-1 infection compared to preinfection (Wilcoxon paired signed-rank test P < .05 [*], P < .01 [**], and P < .001 [***], N = 31). Abbreviations: bFGF, basic 
fibroblast growth factor; Flt, FMS-like tyrosine kinase; GM-CSF, granulocyte-macrophage colony-stimulating factor; HIV-1, human immunodeficiency virus type 1; IP, interferon 
gamma-induced protein; IFN, interferon; IL, interleukin; MCP, monocyte chemoattractant protein; MDC, macrophage-derived chemokine; MIP, macrophage inflammatory protein; 
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Next, analytes with higher PC1 loading (IP-10, IFN-γ, 
IL-12, IL-15, and Flt-1) were analyzed independently to 
assess their prognostic performance in differentiating a 
stronger innate immune response. All analytes demonstrated 
high prognostic value (ROC range, 0.73–0.90), with no sig-
nificant differences in the AUCs (Supplementary Figure 4). 
The best performing analyte and threshold to differentiate 
a stronger innate immune response was IP-10 (466 pg/mL; 
AUC: 0.92 [95% CI: 0.84–1.00]; sensitivity: 84.2% [95% CI: 
60.4–96.6] and specificity: 100.0% [95% CI: 90.3–100.0], 
Figure 6; Supplementary Table 6).
Fiebig II Subpopulation Analysis
Due to the dynamic nature of innate immune responses during 
hAHI, we performed a sensitivity analysis to address the po-
tential confounding effect of combining Fiebig I and II sam-
ples. The analysis was restricted to Fiebig II samples (n = 42) 
and followed the analytical pipeline that was used for the full 
data set. Overall, the results were consistent with the analysis 
of the full data set. Briefly, the most common symptom was 
fever. Volunteers were grouped by LCA into those with (n = 26 
[62%]) and without ARS (n = 16 [38%], Supplementary Figure 
5). Fifteen analytes were significantly elevated during hAHI, 
with IP-10 having 9-fold higher levels compared to preinfection 
levels (Supplementary Figure 6). IP-10, Eotaxin-3, and Flt-1 
were elevated in volunteers with ARS (Supplementary Figure 
7). IP-10 was independently associated with ARS after control-
ling for HIV-1 subtype, age, and risk group (Supplementary 
Table 7). Analytes significantly altered during hAHI and with 
any symptom were analyzed by PCA. These clustered into 3 
PCs indicative of stronger (PC1 and PC2, n = 28 [67%]) and 
Table 2. Logistic Regression Analysis Demonstrating the Association 
Between Specific Analytes and Acute Retroviral Syndrome (ARS) Among 
Volunteers With Hyperacute HIV-1 Infection From Africa (Rwanda, Uganda, 
Zambia, and Kenya) and Sweden (N = 55)
Analyte
Crude Coef.  
(95% CI) P-value
Adjusted Coef.  
(95% CI)a P-value
IL-12 .24 (−.89 to 1.37) .672 … …
IL-15 .83 (−.98 to 2.64) .355 … …
Eotaxin-3 3.20 (1.06–3.81) <.001 3.57 (−.98 to 8.11) .078
IP-10 2.44 (1.07–3.81) <.001 4.71 (.84 – 8.57) .002
Flt-1 −.07 (−1.12 to .98) .891  …
IFN-γ 1.13 (.15 – 2.11) .016 0.58 (-2.10 – 3.26) .671
IL-12p70 1.10 (−.44 to 2.64) .161 … …
IL-13 1.39 (.14–2.63) .020 1.37 (−1.77 to 4.51) .379
Abbreviations: CI, confidence interval; Coef, coefficient; Flt, FMS-like tyrosine kinase; HIV-
1, human immunodeficiency virus type 1; IFN, interferon; IL, interleukin; MSM, men who 
have sex with men. 
aAdjusted for age group (18.0–24.9 vs >25.0 years), HIV-1 env subtypes (Non-A1 vs A1) 
and risk group (Non-MSM vs MSM).
A B
Figure 4. (A) Graph summarizing associations between log10 median plasma analyte concentration when comparing volunteers with and those without AHI symptoms 
(Supplementary Figure 2), and (B) plot illustrating differences in log10 median plasma biomarker concentration between hyperacute HIV-1 infected volunteers with ARS com-
pared to mild ARS (Wilcoxon rank sum test P < .05 [*], P < .01 [**], and P < .001 [***], N = 55). Analytes suggestive of an association with any of the 11 AHI symptoms and 
with ARS (IL-12, IL-15, Eotaxin-3, IP-10, Flt-1, IFN-γ, IL-12p70 and IL-13) were further explored using principal component analysis (PCA). Abbreviations: AHI, acute human 
immunodeficiency virus type 1; ARS, acute retroviral syndrome; bFGF, basic fibroblast growth factor; Flt, FMS-like tyrosine kinase; GM-CSF, granulocyte-macrophage colo-
ny-stimulating factor; HIV-1, human immunodeficiency virus type 1; IFN, interferon; IP, interferon gamma-induced protein; IL, interleukin; MCP, monocyte chemoattractant 
protein; MDC, macrophage-derived chemokine; MIP, macrophage inflammatory protein; PlGF, placental growth factor; TARC, thymus and activation-related chemokine; TNF, 
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comparatively weaker innate immune responses (PC3, n = 14 
[33%], Supplementary Figures 8 and 9; Supplementary Table 
8). Volunteers with stronger innate immune responses had 
increased odds of ARS (adjusted odds ratio [aOR] 11.9 [95% 
CI: 1.1–130.4], P = .019, Supplementary Table 9). Finally, IP-10 
was the best prognostic performing analyte (threshold: 1752 
A B
Figure 5. (A) Graph demonstrating the differentiation of analyte responses by principal component analysis loadings. Volunteers with higher principal component 
(PC) 1 loadings had significantly higher plasma concentration in a majority of the analytes compared to those with higher PC2 loadings (Wilcoxon rank sum test P < .05 
[*], P < .01 [**], and P < .001 [***], N = 55); (B) A schematic illustration of the differentiation of analyte responses into volunteers with and without a cytokine storm; 
and Wilcoxon signed rank test (P < .05 [*], P < .01 [**], P < .005 [***], and P < .0005 [****]; paired/matched signed rank test in green, N = 31). Abbreviations: hbFGF, 
basic fibroblast growth factor; Flt, FMS-like tyrosine kinase; GM-CSF, granulocyte-macrophage colony-stimulating factor; hAHI, hyperacute HIV-1 infection; HIV-1, human 
immunodeficiency virus type 1; IFN, interferon; IL, interleukin; IP, interferon gamma-induced protein; MCP, monocyte chemoattractant protein; MDC, macrophage-derived 
chemokine; MIP, macrophage inflammatory protein; PlGF, placental growth factor; TARC, thymus and activation-related chemokine; TNF, tumor necrosis factor; VEGF, 
vascular endothelial growth factor.
Table 3. Logistic Regression Analysis Demonstrating the Association Between Innate Immune Responses and Acute Retroviral Syndrome (ARS) Among 
Volunteers With Hyperacute HIV-1 Infection From Africa and Sweden (N = 55)
Particulars ARS, n (%) Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value
Innate immune responses Weaker responses 6/19 (32) Ref .007 Ref .003
Stronger responses 25/36 (69) 4.9 (1.5 – 16.3)  7.1 (1.7–28.8)
Fiebig staging Fiebig I 5/13 (38) Ref .137 … …
Fiebig II 26/42 (62) 2.6 (.7 – 9.3)   
Gender Male 28/51 (55) Ref .422 … …
Female 3/4 (75) 2.5 (.2 – 25.3)   
Age group (y) 18.0 – 24.9 13/17 (76) 3.6 (1.0 – 13.1) .040 2.4 (.5–12.1) .264
25.0 + 18/38 (47) Ref  Ref
Year of infection <2009 11/19 (58) Ref .712 … …
2009 – 2010 15/25 (60) 1.1 (.3 – 3.7)   
2011+ 5/11 (45) .6 (.1 – 2.7)   
HIV-1 env subtype Non-A1a 9/22 (41) Ref .059 Ref .176
A1 22/33 (67) 2.9 (1.0 – 8.8)  2.5 (.6 – 9.3)
Ethnicity Non-Africanb 7/13 (54) Ref .834 … …
African 24/42 (57) 1.1 (.3 – 4.0)   
Risk group Non-MSMc 8/21 (38) Ref .031 Ref .084
MSM 23/34 (68) 3.4 (1.1 – 10.6)  3.3 (.8–12.8)
Country Sweden 7/13 (54) Ref .834 … …
Africand 24/42 (57) 1.1 (.3–3.9)   
Abbreviations: CI, confidence interval; HIV-1, human immunodeficiency virus type 1; MSM, men who have sex with men; OR, odds ratio; Ref, reference.
aHIV-1 env subtypes B (n = 8), C (n = 8), D (n = 3), BG (n = 1), A2D (n = 1), and AE (n = 1). 
bCaucasian (n = 12), Asian/Arabian (n = 1). 
cDiscordant couples (n = 14), heterosexual (n = 4), and unknown (n = 3). 
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pg/mL; AUC of 0.82 [95% CI: 0.69–0.95]; sensitivity: 71.4% 
[95% CI: 41.9–91.6] and specificity: 92.9% [95% CI: 76.5–99.1], 
Supplementary Figures 10 and 11; Supplementary Table 10).
DISCUSSION
Our findings are consistent with previous studies reporting 
striking elevation of innate immune markers resulting in 
the well-established cytokine storm during AHI [12–14]. 
In the absence of a gold standard, we applied a holistic sys-
tems approach to differentiate innate immune activation, 
and observed that a stronger immune response during hAHI 
was independently associated with ARS. To our knowledge, 
only one other study has reported associations between in-
nate immune responses during AHI and ARS [26]. Crowell 
et al included 430 volunteers with AHI, a majority (62%) of 
whom were enrolled at Fiebig stage III or later. Five of the 
10 analyzed analytes were included in our analysis (TNF-α, 
IL-6, IL-7, IP-10, and MCP-1). In contrast to our findings, 
TNF-α was elevated in ARS, whereas no association with 
IP-10 was reported. Several factors may explain these differ-
ences. First, because our volunteers were enrolled at Fiebig 
stages I/II, we were able to observe the earliest innate immune 
perturbations, including the cytokine storm, which may have 
been missed by a majority of the volunteers in the study by 
Crowell et  al. Second, Crowell et  al studied participants en-
rolled in Bangkok, Thailand (an HIV-1 CRF01_AE predom-
inant region), whereas we studied participants from Africa 
and Europe infected by various strains of HIV-1 (subtypes A, 
B, C, and D, representing >70% of HIV-1 infections globally) 
[29]. Indeed, varying rates of disease progression have been 
suggested for different subtypes and circulating recombinant 
forms (CRFs) [30]. Third, given the different study settings, 
it is possible that differences in host genetic factors impacted 
innate immune responses differently [31]. Finally, Crowell 
et  al defined ARS as ≥3 symptoms, whereas we considered 
both the number of symptoms and unobserved relatedness 
between symptoms. This may have resulted in a more sensi-
tive differentiation of ARS.
We identified 16 analytes that had significantly higher 
plasma concentrations during hAHI compared to preinfection 
values. Systemic upregulation of innate immune analytes 
during AHI is consistent with literature, and the association 
with ARS may be explained by multiple but related events 
[12–14]. In brief, and during AHI, the virus targets innate 
immune cells including dendritic cells, macrophages, and 
NK cells [9–11]. The result is significant destruction of these 
cells, widespread systemic virus dissemination, and a subse-
quent immunological milieu resulting in activation of innate 
and adaptive immune responses. Further, debris released 
from infected cells and other microbial products are trans-
located across mucosal barriers causing additional systemic 
inflammation and cytokine production [9, 13]. Altogether, 
these processes result in profound damage to cells, blood 
capillaries and mucosal barriers which may explain subse-
quent systemic (eg, fever), lymphatic (eg, lymphadenop-
athy), gastrointestinal (eg, diarrhea), musculoskeletal (eg, 
myalgia), and neurologic (eg, headache) symptoms. Notably, 
cytokine responses are activated and peak within 2 weeks of 
HIV-1 infection [13], whereas symptoms start manifesting 
2–3 weeks after infection [3, 32], suggesting that systemic 
innate immune activation is a precursor for symptomatic 
manifestations.
Figure 6. Graphs demonstrating distribution, performance (sensitivity and specificity) and threshold of analytes (IL-12, IL-15, Flt-1, IP-10, and IFN-γ) indicative of a stronger 
innate immune response. Analytes and threshold with both sensitivity and specificity of more than 80% were further explored. Abbreviations: Flt, FMS-like tyrosine kinase; 
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The observed IP-10 elevation among volunteers with ARS is 
consistent with literature [14, 33]. However, its role in the in-
duction of AHI symptoms is less understood. IP-10 is induced 
during the eclipse phase of AHI by innate immune cells in re-
sponse to IFN-γ stimulation [34]. It is therefore not surprising 
that IP-10 clustered closely with IFN-γ during PCA analysis. 
IP-10 induction increases exponentially and in parallel with 
HIV-1 RNA but prior to symptom manifestation [12]. In turn, 
IP-10 induces chemotaxis, apoptosis, cell growth inhibition, and 
angiostasis of different immune cells contributing to the dam-
aging immunological milieu as described above. The role of IP-10 
in disease pathogenesis is not unique to HIV-1; elevated IP-10 
has been documented in a diverse range of virus infections, such 
as hepatitis C virus (HCV) infection, respiratory infections, and 
the more recent severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) infection [35–37]. The utility of IP-10 as a di-
agnostic marker for infectious diseases has also been explored. 
For instance, and in a meta-analysis, IP-10 has been suggested as 
a diagnostic marker for differentiating active from latent tuber-
culosis [38]. IP-10 has also been suggested as a marker for detec-
tion of AHI and for virus load monitoring [33, 39]. Yet the role 
of IP-10 as a biomarker in the differentiation of stronger immune 
responses remains undocumented. We propose consideration of 
IP-10 as a candidate marker in the differentiation of stronger in-
nate immune responses at a threshold of >466 pg/mL.
Our study is not without limitations. First, the majority of our 
volunteers were missing HIV-1 RNA data. HIV-1 RNA increases 
and peaks 2–3 weeks after infection [2–5]. As HIV-1 viremia 
increases, pro-inflammatory cytokines and chemokines are in-
duced, suggesting a possible correlation, as has been demon-
strated between HIV-1 RNA and IP-10 [12]. HIV-1 RNA is also 
associated with ARS [26]. Further studies to disentangle the re-
lationship between HIV-1 RNA, innate immune perturbations, 
and ARS are therefore warranted. Second, although our strict 
Fiebig I/II inclusion criteria enabled us to elucidate very early 
immune responses, it is possible that peak activation of analytes 
with delayed response may have been missed [12, 13]. Third, it 
is possible that volunteers seeking hospital care are more likely 
to present with ARS compared to those from a routine longi-
tudinal cohort. However, there was no significant difference in 
the number of symptoms reported by the hospital volunteers 
compared to routine cohort volunteers (median, 5 [IQR, 3–6] 
vs 4 [IQR, 0–7] symptoms per volunteer respectively, P = .610). 
Finally, our small sample size and potential bias toward male vo-
lunteers (93% of the study population) warrants validation of our 
findings in larger and more sex-balanced AHI studies.
In conclusion, we applied holistic systems approaches to eluci-
date ARS from AHI symptoms and to disentangle the myriad of 
complex but related pathways of soluble innate immune markers. 
We found compelling evidence of an association between 
stronger innate immune responses and ARS. Specifically, plasma 
IP-10 was profoundly activated during AHI and associated with 
ARS. Furthermore, and in the absence of a gold standard, we also 
identified plasma IP-10 as a candidate biomarker in the differen-
tiation of a stronger innate immune response. Our findings pro-
vide further insights into early immune responses during hAHI, 
their role in the regulation of ARS, and may have implications for 
the design of vaccine candidates that harness innate immunity 
for virus neutralization or replication control.
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